Objective: To analyze the pharmaceutical care process of anti-infective treatment in a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, so as to provide reference for the treatment of such patients. Methods: After analyzing the drug susceptibility test report of a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, the clinical pharmacist suggested another drug susceptibility test according to the drug susceptibility test standards of non-tuberculous mycobacterium (NTM). Through a combination with the drug pharmacokinetic characteristics, the treatment regimen was adjusted from cefoxitin + imipenem/cilastatin sodium + ethambutol + clarithromycin to cefoxitin + imipenem/cilastatin sodium + amikacin nebulized inhalation + azithromycin + tigecycline, improving the condition of the patient after 20 days of treatment. According to the drug susceptibility test results of NTM, the anti-infective treatment regimen was adjusted to cefoxitin + amikacin + azithromycin + tigecycline + moxifloxacin based on the patient's condition, after 20 days of treatment, the patient was discharged under further improved condition and was transferred to a community hospital for further treatment. The clinical pharmacist also participated in evaluating and preventing adverse drug reactions in the treatment process, and provided medication guidance for the patient after discharge. Results: The physician followed the advice of the clinical pharmacist and adjusted the treatment regimen twice. After 3 months of treatment, the patient's condition was well controlled and no serious adverse reactions occurred. Conclusion: The clinical pharmacist has participated in the diagnosis and treatment process of a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, developed personalized anti-infective treatment regimens for the patient, and achieved good effects, reflecting the professional ability and service level of the clinical pharmacist, and providing ideas for the clinical diagnosis and treatment of multidrug-resistant non-tuberculous mycobacterium lung disease.
Key words
multidrug-resistant /
non-tuberculous mycobacterium lung disease /
pharmaceutical care
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Daley CL, Iaccarino JM, Lange C, et al.Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Clin Infect Dis, 2020, 71(4): e1-e36.
[2] Zhou L, Xu D, Liu HC, et al.Trends in the prevalence and antibiotic resistance of non-tuberculous mycobacteria in mainland China, 2000-2019: systematic review and meta-analysis[J]. Front Public Heath, 2020, 8: 295.
[3] Gopalaswamy R, Shanmugam S, Mondal R, et al.Of tuberculosis and non-tuberculous mycobacterial infections-a comparative analysis of epidemiology, diagnosis and treatment[J]. J Biomed Sci, 2020, 27(1): 1-17.
[4] 中华医学会结核病学分会.非结核分枝杆菌病诊断与治疗指南(2020 年版)[J].中华结核和呼吸杂志,2020,43(11):918-946.
[5] Brown-Elliott BA, Philley JV. Rapidly growing mycobacteria[J]. Microbiol Spectr, 2017, 5(1): Rapidly1-Rapidly19.
[6] Wallace RJ, Dukart G, Brown-Elliott BA, et al.Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections[J]. J Antimicrob Chemother, 2014, 69(7): 1945-1953.
[7] Brown-Elliott BA, Wallace RJ Jr.Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria[J]. Clin Microbiol Rev, 2002, 15(4): 716-746.
[8] Falkinham JO 3rd. Challenges of NTM drug development[J]. Front Microbiol, 2018, 9: 1613.
[9] Jarlier V, Gutmann L, Nikaido H.Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae[J]. Antimicrob Agents Chemother, 1991, 35(9): 1937-1939.
[10] Brown-Elliott BA, Nash KA, Wallace RJ Jr.Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria[J]. Clin Microbiol Rev, 2012, 25(3): 545-582.
[11] Johansen MD, Herrmann JL, Kremer L.Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus[J]. Nat Rev Microbiol, 2020, 18(7): 392-407.
[12] Projan SJ.Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent[J]. Pharmacotherapy, 2000, 20(9 Part 2): 219S-223S.
[13] Brown-Elliott BA, Woods GL.Antimycobacterial susceptibility testing of nontuberculous mycobacteria[J]. J Clin Microbiol, 2019, 57(10): e00834-e00819.
[14] Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)[J]. Thorax, 2017, 72(Suppl 2): ii1-ii64.
[15] Olivier KN, Shaw PA, Glaser TS, et al.Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease[J]. Ann Am Thorac Soc, 2014, 11(1): 30-35.
[16] 中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志,2018,41(6):409-446.
[17] Winthrop KL, Ku JH, Marras TK, et al.The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease[J]. Eur Respir J, 2015, 45(4): 1177-1179.
[18] Gerson SL, Kaplan SL, Bruss JB, et al.Hematologic effects of linezolid: summary of clinical experience[J]. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726.
[19] 林江涛,张永明,王长征,等.大环内酯类药物的抗菌外作用与临床应用专家共识[J].中华内科杂志,2017,56(7):546-557.
[20] Story-Roller E, Galanis C, Lamichhane G.β-lactam combinations that exhibit synergy against Mycobacteroides abscessus clinical isolates[J]. Antimicrob Agents Chemother, 2021, 65(4): e02545-20.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(1549 KB)
